Lionel Groussin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7887658/publications.pdf

Version: 2024-02-01

36	1,328	15	34
papers	citations	h-index	g-index
39	39	39	2174
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	KDM1A inactivation causes hereditary food-dependent Cushing syndrome. Genetics in Medicine, 2022, 24, 374-383.	2.4	27
2	Multiple endocrine neoplasia type 1 or 4 : detection of hyperfunctioning parathyroid glands with $18 { m F}$ -fluorocholine PET/CT, illustrative cases and pitfalls. Quarterly Journal of Nuclear Medicine and Molecular Imaging, 2022, , .	0.7	3
3	18F-fluorocholine PET/CT and conventional imaging in primary hyperparathyroidism. Diagnostic and Interventional Imaging, 2022, 103, 258-265.	3.2	3
4	Practice patterns for chronic hypoparathyroidism: data from patients and physicians in France. Endocrine Connections, 2022, 11 , .	1.9	3
5	Redifferentiating Effect of Larotrectinib in <i>NTRK</i> Rearranged Advanced Radioactive-lodine Refractory Thyroid Cancer. Thyroid, 2022, 32, 594-598.	4.5	19
6	Noninvasive Prenatal Diagnosis of a Paternally Inherited <i>MEN1</i> Pathogenic Splicing Variant. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e1367-e1373.	3.6	1
7	Amiodarone-induced thyrotoxicosis. Annales D'Endocrinologie, 2021, 82, 163-166.	1.4	6
8	A pheochromocytoma wrapped in an IgG4-related disease. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 929-930.	6.4	0
9	Lung carcinoid tumors with Diffuse Idiopathic Pulmonary NeuroEndocrine Cell Hyperplasia (DIPNECH) exhibit pejorative pathological features. Lung Cancer, 2021, 156, 117-121.	2.0	3
10	Selpercatinib-Enhanced Radioiodine Uptake in RET-Rearranged Thyroid Cancer. Thyroid, 2021, 31, 1603-1604.	4.5	10
11	Larotrectinib-Enhanced Radioactive Iodine Uptake in Advanced Thyroid Cancer. New England Journal of Medicine, 2020, 383, 1686-1687.	27.0	43
12	¹⁸ Fâ€fluorocholine PET/CT in MEN1ÂPatients with Primary Hyperparathyroidism. World Journal of Surgery, 2020, 44, 3761-3769.	1.6	25
13	Recommendations for Diagnosis and Treatment of Pseudohypoparathyroidism and Related Disorders: An Updated Practical Tool for Physicians and Patients. Hormone Research in Paediatrics, 2020, 93, 182-196.	1.8	42
14	Management of thyroid dysfunctions in the elderly. French Endocrine Society consensus statement 2019. Long version. Annales D'Endocrinologie, 2020, 81, 89-100.	1.4	9
15	Management of thyroid dysfunctions in the elderly. French Endocrine Society consensus 2019 guidelines. Short version. Annales D'Endocrinologie, 2020, 81, 511-515.	1.4	4
16	Redifferentiation of radioiodine-refractory thyroid cancers. Endocrine-Related Cancer, 2020, 27, R113-R132.	3.1	58
17	An Ectopic Parathyroid Adenoma Mimicking a Carotid Body Paraganglioma. Journal of the Endocrine Society, 2020, 4, bvaa143.	0.2	1
18	Genetics of Human Thyroid Cancer Cell Linesâ€"Letter. Clinical Cancer Research, 2019, 25, 6882-6882.	7.0	0

#	Article	IF	CITATIONS
19	A Hungry Bone Syndrome Predicted by 18F-Fluorocholine PET/CT. Clinical Nuclear Medicine, 2019, 44, 903-904.	1.3	1
20	18F-FDG PET reveals an adrenocortical carcinoma in a bilateral adrenal multinodular disease. Endocrine, 2019, 63, 188-189.	2.3	4
21	MET overexpression and activation favors invasiveness in a model of anaplastic thyroid cancer. Oncotarget, 2019, 10, 2320-2334.	1.8	11
22	Visualization of Macroprolactinoma by 18F-Fluorocholine PET/CT in a Patient With Multiple Endocrine Neoplasia Type 1. Journal of the Endocrine Society, 2018, 2, 1170-1172.	0.2	3
23	Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement. Nature Reviews Endocrinology, 2018, 14, 476-500.	9.6	224
24	Long-Term Control of Hypercortisolism by Vandetanib in a Case of Medullary Thyroid Carcinoma with a Somatic <i>RET</i> Mutation. Thyroid, 2017, 27, 587-590.	4.5	17
25	Next Generation Sequencing and Association Studies in Familial Nonmedullary Thyroid Carcinoma: Let's Choose Appropriate Controls. European Thyroid Journal, 2017, 6, 221-224.	2.4	2
26	Polyendocrinopathy Resulting From Pembrolizumab in a Patient With a Malignant Melanoma. Journal of the Endocrine Society, 2017, 1, 646-649.	0.2	75
27	Restoring Radioiodine Uptake in BRAF V600E–Mutated Papillary Thyroid Cancer. Journal of the Endocrine Society, 2017, 1, 285-287.	0.2	20
28	DUSP5 and DUSP6, two ERK specific phosphatases, are markers of a higher MAPK signaling activation in BRAF mutated thyroid cancers. PLoS ONE, 2017, 12, e0184861.	2.5	46
29	Long-term outcome after adrenalectomy for incidentally diagnosed subclinical cortisol-secreting adenomas. Surgery, 2016, 160, 397-404.	1.9	5
30	Vemurafenib for BRAFV600E-positive metastatic papillary thyroid cancer. Lancet Oncology, The, 2016, 17, e468.	10.7	3
31	Value of 18-F-FDG PET/CT and CT in the Diagnosis of Indeterminate Adrenal Masses. International Journal of Endocrinology, 2015, 2015, 1-8.	1.5	24
32	Dual Specificity Phosphatase 5, a Specific Negative Regulator of ERK Signaling, Is Induced by Serum Response Factor and Elk-1 Transcription Factor. PLoS ONE, 2015, 10, e0145484.	2.5	32
33	Redifferentiation of Iodine-Refractory BRAF V600E-Mutant Metastatic Papillary Thyroid Cancer with Dabrafenibâ€"Letter. Clinical Cancer Research, 2015, 21, 5639-5639.	7.0	3
34	The Great Imitator in Endocrinology: A Painful Hypophysitis Mimicking a Pituitary Tumor. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 2837-2840.	3.6	16
35	The 10 Hounsfield units unenhanced computed tomography attenuation threshold does not apply to cortisol secreting adrenocortical adenomas. European Journal of Endocrinology, 2015, 173, 325-332.	3.7	21
36	Integrated genomic characterization of adrenocortical carcinoma. Nature Genetics, 2014, 46, 607-612.	21.4	560

3